Business Context and Reporting Period
OraSure Technologies, Inc. filed this Form 8-K on February 15, 2002, to disclose preliminary financial results for the full year and fourth quarter ended December 31, 2001. The company operates in the oral fluid substance abuse and infectious disease testing markets.
Key Financial Metrics
| Metric | Full Year 2001 | Q4 2001 |
|---|---|---|
| Revenue | $32.6 million | $8.1 million |
| Net Loss | $3.7 million ($(0.10) per share) | $2.3 million ($(0.06) per share) |
| Gross Margin | 62% | 53% |
| Operating Expenses (excl. merger charges) | $24 million | $6.8 million |
The filing does not provide specific data on cash flow, total debt, or liquidity positions.
Material Changes vs. Prior Period
- Revenue Growth: Full-year revenue increased 20% and Q4 revenue increased 9% compared to the same periods in 2000 (excluding discontinued Serum Western Blot product revenue from 2000).
- Profitability Improvement: Net loss narrowed significantly from $12.7 million in 2000 to $3.7 million in 2001. The 2000 loss included $7.6 million in merger-related charges.
- Margin Volatility: While full-year gross margin improved to 62%, Q4 margin dropped to 53% due to a $0.6 million inventory reserve for OraQuick(R) HIV tests.
- Expense Management: Operating expenses remained flat for the full year and declined 4% in Q4 compared to the prior year (excluding 2000 merger charges).
Outlook, Risks, and Unusual Items
Guidance and Outlook
Management targets revenue growth of up to 30% for 2002, aiming for approximately $42 million. The company expects to achieve profitability in the second half of 2002 and for the full year.
Unusual Items and Contingencies
The Q4 gross margin decline was driven by a $0.6 million inventory reserve. This resulted from terminating an agreement with an African distributor for OraQuick(R) HIV tests due to failure to meet purchase commitments and concerns regarding product shelf-life.
Risks
Forward-looking statements are subject to risks including regulatory approval timing, market acceptance of new products, distributor startup delays, patent litigation, product liability, and general economic conditions.
Investor Verification Checklist
- Verify the status of the new distribution channel for OraQuick(R) in Africa to assess the recoverability of remaining inventory.
- Confirm the timeline for regulatory approvals required to meet the 2002 revenue and profitability targets.
- Review the specific impact of the discontinued Serum Western Blot product on year-over-year revenue comparisons.
- Monitor the startup progress of new distributors mentioned as a dependency for 2002 results.